Immunome Inc

For the period ended Sep 30, 2024. Filed Nov 13, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 13, 2024

IMNM$19.36+3.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Page
	PART I – FINANCIAL INFORMATION

Item 1. · Financial Statements (Unaudited) ·
		- Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023	3
		- Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2024 and 2023	4
		- Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Three and Nine Months Ended September 30, 2024 and 2023	5
		- Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2024 and 2023	7
		- Notes to Condensed Consolidated Financial Statements	9

Item 2.		Management’s Discussion and Analysis of Financial Condition and Results of Operations.	23
Item 3.		Quantitative and Qualitative Disclosures about Market Risk.	35
Item 4.		Controls and Procedures.	35

PART II – OTHER INFORMATION ·

Item 1.		Legal Proceedings.	36
Item 1A.		Risk Factors.	36
Item 2.		Unregistered Sales of Equity Securities and Use of Proceeds.	95
Item 3.		Defaults Upon Senior Securities.	95
Item 4.		Mine and Safety Disclosures.	95
Item 5.		Other Information.	95
Item 6.		Exhibits.	96

SIGNATURES ·

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.

About this filing

Table of Contents